Eni SpA vs Relay Therapeutics Inc. Common Stock — how do they compare? Eni SpA trades at $55.64 (market cap $78.10B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Eni SpA is far larger — about 19.8× Relay Therapeutics Inc. Common Stock's market cap, and Eni SpA pays a 4.52% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| E | RLAY | |
|---|---|---|
Market Cap | $78.10B | $3.94B |
Volume | 296,516 | 3,432,928 |
Sector | Energy | Health |
52-Week High | $57.61 | $20.75 |
52-Week Low | $34.03 | $6.03 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $102.75B | $3.06B |
Dividend Yield | 4.52% | — |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $55.62, up 1.96% today, amid a bearish technical signal. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97% in 2026. The company maintains solid cash flow and a low P/E of 12.53. Recent news highlights expansion in humanoid robotics, LNG projects in Argentina, and fuel discounts in Italy, indicating strategic diversification and customer support initiatives.
The outlook is mixed; valuation appears attractive with low multiples, and analyst consensus leans hold (61.53%). However, declining revenue, recent earnings misses, and bearish technicals pose near-term risks. Upside depends on execution of new projects and stabilization of energy markets, while volatility in oil prices remains a key sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →